Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

NCT02064725 is registered in ClinicalTrials.gov with Kevelt AS as lead sponsor.

NCT NCT02064725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02064725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
Lead sponsor
Kevelt AS
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2014
Completion date
July 31, 2018
Enrollment
8 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or persistent endometrial carcinoma